11,946 Shares in Pro-Dex, Inc. (NASDAQ:PDEX) Acquired by American Century Companies Inc.

American Century Companies Inc. purchased a new stake in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,946 shares of the medical instruments supplier's stock, valued at approximately $558,000. American Century Companies Inc. owned approximately 0.37% of Pro-Dex as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Ritholtz Wealth Management acquired a new stake in shares of Pro-Dex in the fourth quarter valued at approximately $572,000. FMR LLC lifted its stake in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after buying an additional 1,028 shares during the last quarter. Geode Capital Management LLC grew its stake in Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock valued at $819,000 after buying an additional 2,296 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Pro-Dex in the 4th quarter valued at about $202,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after acquiring an additional 529 shares during the period. Institutional investors own 15.28% of the company's stock.

Insider Activity at Pro-Dex

In related news, Director Raymond E. Cabillot sold 7,674 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $45.00, for a total transaction of $345,330.00. Following the sale, the director now owns 310,978 shares in the company, valued at $13,994,010. The trade was a 2.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 42,450 shares of company stock valued at $1,959,193 over the last ninety days. 47.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Pro-Dex from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th.

Pro-Dex Price Performance

Shares of NASDAQ PDEX traded down $0.44 during mid-day trading on Thursday, reaching $60.89. The company had a trading volume of 4,951 shares, compared to its average volume of 35,790. Pro-Dex, Inc. has a one year low of $16.83 and a one year high of $65.87. The business's 50-day simple moving average is $45.34 and its 200 day simple moving average is $42.87. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. The firm has a market cap of $198.56 million, a price-to-earnings ratio of 30.29 and a beta of 0.40.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, research analysts predict that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.